FOXP3 and neoplasm: To elucidate the spatial differences of immune composition among patients who received or did not receive neoadjuvant chemotherapy, we analyzed the status of CD3, CD8, CD4, and FOXP3 in the tumor center (TC) and the invasive front (IF) in a panel of serial section from 42 PDACs (Table S1), 14 of which derived from patients who received neoadjuvant chemotherapy (Table S2).